The Board of Directors

Duncan Moore 

Moore, born 1959, is Chairman of the Board of Oncology Venture Sweden AB (publ) since 2015, and since February 2015 Chairman of the Board of the wholly owned subsidiary Oncology Venture ApS. Moore is a partner in the company East West Capital Partners and has previously worked as Global Head of Healthcare Research at Morgan Stanley. Moore has over twenty years experience in capital markets analysis within health care. Owns 76.276 shares, however holds 20,000 warrants in the Company.

Sanjeevi Carani 

Carani, born 1958, is a member of the Board of Directors of Oncology Venture Sweden AB (publ) since 2015, and since February a member of the Board of the wholly owned subsidiary Oncology Venture ApS. Carani is a professor at Karolinska Institute and for several years has been head of the Molecular Immunogenetics Research Group at Karolinska University Hospital in Stockholm. Owns no shares, however holds 10,000 warrants in the Company.

SteenKnudsen

Steen Knudsen

Knudsen, born 1961, is a member of the Board of Directors of Oncology Venture Sweden AB (publ) since 2015, and as of May 2015, will also be a member of the Board of Directors of the wholly owned subsidiary Oncology Venture ApS. Knudsen is also one of the founders of Oncology Venture ApS, and also co-founder of Medical Prognosis Institute A/S. Knudsen is a Professor of Systems Biology with extensive expertise in mathematics, bioinformatics, biotechnology, and systems biology. Furthermore, Knudsen is the inventor of Drug Response Prediction which Oncology Venture has a license from Medical Prognosis Institute A/S. Steen Knudsen represents the majority shareholder, Medical Prognosis Institute A/S. Owns no shares, however holds 10,000 warrants in the Company.

Ulla Hald Buhl 

Hald Buhl, born 1964, is a member of the Board of Directors of Oncology Venture Sweden AB (publ) since 2015, and since March 2015 a member of the Board of Directors of the wholly owned subsidiary Oncology Venture ApS. Hald Buhl has a broad background in clinical trials, organisation management and communications. Hald Buhl has previously been in charge of TopoTarget A/S’s investor relations department and is currently active in this area in both Swedish WNT Research AB (listed on AktieTorget) as well as Danish Medical Prognosis Institute A/S (listed on NASDAQ First North in Copenhagen). During 1999-2001, Hald Buhl worked as a Team Leader in oncology at AstraZeneca A/S and during 2001-2005 Hald Buhl was the head of the regulatory department of TopoTarget A/S. Owns 20%* of Buhl Krone Holding ApS ** which owns 1,227,240 shares of the Company. Holds 10,000 warrants in the Company.

* The remaining 80% is owned by Peter Buhl Jensen, who is Ulla Hald Buhl’s husband and CEO of Oncology Venture.

** The same corporate registration number as Buhl Oncology ApS.

Peter Birk 

Birk, born 1965, is a member of the Board of Directors of Oncology Venture Sweden AB (publ) since 2015, and since 2015 member of the Board of Directors of the wholly owned subsidiary Oncology Venture ApS. Birk represents the shareholder, Pre-Seed Innovation. During the last fifteen years, Birk has held senior positions in various biotechnology companies and thereby acquired extensive knowledge regarding the value chain in biotechnology, both the scientific and the business side. Birk is active in business development, investments, research and development planning, as well as managing, monitoring and project evaluation, etc., in companies in the field of biotechnology and life sciences. Moreover, Birk is extensively engaged in research and development projects in a number of areas, among others include cancer, Alzheimer disease, infectious diseases, development of vaccines, pharmaceutical drug development, to name a few.